NAUT logo

NAUTILUS BIOTECHNOLOGY INC

NAUTNASDAQ
πŸ† #2999 by market capEarnings Feb 24 Β· PreUS Equity
$3.21β–² $0.32 (+11.07%)
Market closed Β· at close
πŸ””
Track NAUT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 11.1%
7dβ–² 23.2%
14dβ–² 49.3%
30dβ–² 136.0%
ytdβ–² 64.6%
1yβ–² 121.4%
🏦Market Cap
$409M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$2.80 – $3.34
52-Week Range
$0.84 – $4.31
Volume (shares)
15,100,307
Avg Volume (shares)
β€”
Shares Outstanding
127.3M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$234,000
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-0.45
Dividend Yield
β€”
Dilution (1yr)
+0.4%
NAUT logo

NAUTILUS BIOTECHNOLOGY INC

NAUT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$67Mβ–Ό βˆ’18.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$52Mβ–Ό βˆ’15.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
126.3Mβ–² +0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$18Mβ–Ό βˆ’$15M YoY
StockOtter Β· stockotter.space

About NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy4
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Seeking AlphaΒ·7h ago

Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch

NAUT is extending Voyager from tau into oncology, which I think will give it more applications for its targeted proteoform platform. NAUT also has research collaborations and SEEDS participation. In my view, this corrobo

Seeking AlphaΒ·1d ago

Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript

MarketBeatΒ·1d ago

Nautilus Biotechnology Q3 Earnings Call Highlights

Nautilus Biotechnology NASDAQ: NAUT reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin taking

GlobeNewsWireΒ·2d ago

Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium

Nautilus expects to receive up to $6 million to bring its Voyagerβ„’ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics Nautilus exp

GlobeNewsWireΒ·2d ago

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results

SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended Sept

GlobeNewsWireΒ·13d ago

Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or β€œNautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results fo